Providers who know your name Real nurse practitioners and clinicians, based in the U.S
In an invited commentary on this study, the authors discussed the mixed literature on the impact of GLP-1 receptor agonists and risks of developing or progressing AMD, and raised some concerns regarding this latest research
[Abstract]2025;3(1):10
Starting December of 2025, its also approved as a daily pill
Areas Requiring Further Investigation Further research is needed to clarify long-range receptor signaling behavior, tissue-specific pathway effects, molecular signaling durability, model-to-human translation, and how findings vary across study designs
1, Table 1, Extended Data Tables 1 and 2, and Supplementary Section 4) and substance-use disorders (via modulation of dopaminergic pathways of reward, impulse control and decision-making